|
|
Blood, 1 August 2004, Vol. 104, No. 3, pp. 822-828.
Prepublished online as a Blood First Edition Paper on April 15, 2004; DOI 10.1182/blood-2003-11-3938.
Previous Article | Next Article 
Submitted November 17, 2003
Accepted March 30, 2004
Defective DNA Mismatch Repair in Acute Myeloid Leukemia/Myelodysplastic Syndrome After Organ Transplantation
Judith Offman, Gerhard Opelz, Bernd Doehler, David Cummins, Ozay Halil, Nicholas R Banner, Margaret M Burke, Dianne Sullivan, Peter Macpherson, and Peter Karran*
Clare Hall Laboratories, Cancer Research UK London Research Institute, South Mimms, United Kingdom
Abteilung Transplantations-immunologie, Institut fur Immunologie, Heidelberg, Germany
Harefield Hospital, Harefield, United Kingdom
* Corresponding author; email: peter.karran{at}cancer.org.uk.
Immunosuppression following organ transplantation is an acknowledged risk factor for skin cancer and lymphoma. We examined whether there was also an excess of leukemia in transplant patients and whether this might be related to a particular immunosuppressive treatment. Data from more than 170000 patients indicated that organ transplantation is associated with a significantly increased risk of acute myeloid leukemia (AML). AML was more frequent following heart and/or lung transplant than kidney transplant and was associated with immunosuppression by azathioprine - a thiopurine prodrug. Cellular resistance to thiopurines is associated with DNA mismatch repair (MMR) deficiency. We demonstrate that thiopurine treatment of human cells in vitro selects variants with defective MMR. Consistent with a similar selection in patients bone marrow, seven of seven transplant-related AML/myelodysplastic syndrome (MDS) cases exhibited the microsatellite instability (MSI) that is diagnostic for defective MMR. Since MSI occurs infrequently in de novo AML, we conclude that the selective proliferation of MMR-defective, azathioprine-resistant myeloid cells may contribute significantly to the development of AML/MDS in organ transplant patients. The identification of azathioprine as a risk factor for AML/MDS suggests that the incidence of post-transplant AML/MDS might be reduced by discontinuing its use as an immunosuppressant.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Therapy-related myeloid leukemia: stochastic or idiosyncratic?
- Richard A. Larson
Blood 2004 104: 602-603.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
H Sokol and L Beaugerie
Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle
Gut,
October 1, 2009;
58(10):
1427 - 1436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Czader and A. Orazi
Therapy-Related Myeloid Neoplasms
Am J Clin Pathol,
September 1, 2009;
132(3):
410 - 425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nguyen, P. M. Vacek, P. O'Neill, R. B. Colletti, and B. A. Finette
Mutagenicity and Potential Carcinogenicity of Thiopurine Treatment in Patients with Inflammatory Bowel Disease
Cancer Res.,
September 1, 2009;
69(17):
7004 - 7012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Larson
Therapy-related myeloid neoplasms
Haematologica,
April 1, 2009;
94(4):
454 - 459.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kenyon and S. L. Gerson
The role of DNA damage repair in aging of adult stem cells
Nucleic Acids Res.,
December 26, 2007;
(2007)
gkm1064v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Svrcek, J. El-Bchiri, A. Chalastanis, E. Capel, S. Dumont, O. Buhard, C. Oliveira, R. Seruca, C. Bossard, J.-F. Mosnier, et al.
Specific Clinical and Biological Features Characterize Inflammatory Bowel Disease Associated Colorectal Cancers Showing Microsatellite Instability
J. Clin. Oncol.,
September 20, 2007;
25(27):
4231 - 4238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Karran
Thiopurines, DNA damage, DNA repair and therapy-related cancer
Br. Med. Bull.,
February 2, 2007;
(2007)
ldl020v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Larson
Etiology and Management of Therapy-Related Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
453 - 459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Offman, K. Gascoigne, F. Bristow, P. Macpherson, M. Bignami, I. Casorelli, G. Leone, L. Pagano, S. Sica, O. Halil, et al.
Repeated Sequences in CASPASE-5 and FANCD2 but not NF1 Are Targets for Mutation in Microsatellite-Unstable Acute Leukemia/Myelodysplastic Syndrome
Mol. Cancer Res.,
May 1, 2005;
3(5):
251 - 260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Licht and D. W. Sternberg
The Molecular Pathology of Acute Myeloid Leukemia
Hematology,
January 1, 2005;
2005(1):
137 - 142.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|